Friday, 16 October 2026European Markets

GLINTT And NEDAP Have A High Dividend Yield And Return On Equity In The Technology Sector.

Loading stream...

(VIANEWS) - GLINTT (GLINT.LS) is among this list of stock assets with the highest dividend rate and return on equity on the Technology sector.

Financial Asset Price Forward Dividend Yield Return on Equity
GLINTT (GLINT.LS) €0.28 5.93% 4.84%
NEDAP (NEDAP.AS) €58.00 5.26% 23.16%

Several Euronext companies pay out dividends to its shareholders. The dividend yield is a dividend to price ratio showing how much a company pays out in dividends each year.

1. GLINTT (GLINT.LS)

5.93% Forward Dividend Yield and 4.84% Return On Equity

Glintt - Global Intelligent Technologies, S.A. provides IT and consulting services in Portugal and internationally. The company offers business consulting services, such as pharmacy management, continuous, diagnostic, and project consulting; and IT consulting services, including applications and technology consulting, business process management, and data analytics. It also provides IT infrastructure services comprising cloud and datacenter, service and application management, networking and security, and information security; physical design and automation, and software solutions; and integrated application and equipment support services. The company primarily serves the healthcare, pharma, financial services, and telecommunications markets, as well as the public sector. Glintt - Global Intelligent Technologies, S.A. was incorporated in 1995 and is based in Sintra, Portugal.

Earnings Per Share

As for profitability, GLINTT has a trailing twelve months EPS of €0.04.

PE Ratio

GLINTT has a trailing twelve months price to earnings ratio of 7.05. Meaning, the purchaser of the share is investing €7.05 for every euro of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 4.84%.

More news about GLINTT.

2. NEDAP (NEDAP.AS)

5.26% Forward Dividend Yield and 23.16% Return On Equity

Nedap N.V., together with its subsidiaries, develops and supplies smart technological solutions in the Netherlands, Germany, rest of Europe, North America, and internationally. The company provides software services that allow healthcare professionals to interconnect; hardware and software solutions for vehicle identification systems; and technological solutions for the dairy farming and pig farming industries. It also offers lighting solutions and UV lamp driver technologies; and RFID solutions for retailers. In addition, the company provides access control and security systems for companies and institutions. Further, it offers workforce management software, a cloud-based software for timesheet processing, employee scheduling, and access control. The company was founded in 1929 and is headquartered in Groenlo, the Netherlands.

Earnings Per Share

As for profitability, NEDAP has a trailing twelve months EPS of €3.17.

PE Ratio

NEDAP has a trailing twelve months price to earnings ratio of 18.3. Meaning, the purchaser of the share is investing €18.3 for every euro of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 23.16%.

Moving Average

NEDAP's worth is higher than its 50-day moving average of €57.44 and higher than its 200-day moving average of €57.15.

More news about NEDAP.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com